Immunologic Research

, Volume 42, Issue 1, pp 166–181

Genetic engineering of T cells for adoptive immunotherapy

Authors

  • Angel Varela-Rohena
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
  • Carmine Carpenito
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
  • Elena E. Perez
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
  • Max Richardson
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
  • Richard V. Parry
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
  • Michael Milone
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
  • John Scholler
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
  • Xueli Hao
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
  • Angela Mexas
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
  • Richard G. Carroll
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
  • Carl H. June
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
    • Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of Pennsylvania
Article

DOI: 10.1007/s12026-008-8057-6

Cite this article as:
Varela-Rohena, A., Carpenito, C., Perez, E.E. et al. Immunol Res (2008) 42: 166. doi:10.1007/s12026-008-8057-6

Abstract

To be effective for the treatment of cancer and infectious diseases, T cell adoptive immunotherapy requires large numbers of cells with abundant proliferative reserves and intact effector functions. We are achieving these goals using a gene therapy strategy wherein the desired characteristics are introduced into a starting cell population, primarily by high efficiency lentiviral vector-mediated transduction. Modified cells are then expanded using ex vivo expansion protocols designed to minimally alter the desired cellular phenotype. In this article, we focus on strategies to (1) dissect the signals controlling T cell proliferation; (2) render CD4 T cells resistant to HIV-1 infection; and (3) redirect CD8 T cell antigen specificity.

Keywords

Lentiviral vectorCD28PD-1TCRChimeric immunoreceptorZinc-finger nucleaseNOG miceImmunotherapyAdoptive T cell therapy

Copyright information

© Springer Science+Business Media, LLC 2008